TRDA

Entrada TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$4.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Sentiment has turned decisively cautious after the May 7, 2026 readout: company materials framed Cohort 1 as positive, but trusted coverage tied the >50% stock drop to disappointment around dystrophin magnitude and pediatric exposure versus expectations. With no reliable post-print analyst revision set available in the checked evidence and coverage still thin, TRDA now looks more like a monitoring situation than a clean rebound thesis until mid-2026 and year-end follow-up data clarify whether the PK explanation truly rescues efficacy expectations.

RankAlpha Sentiment Codex - 2026-05-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-readout revision cycle may keep shares volatile after the May 7 resetHigh impact

Near-term trading is likely to stay headline-driven after TRDA lost more than half its value on May 7, 2026 as analysts and investors focused on lower-than-expected dystrophin and drug-exposure data despite favorable safety and early functional signals; the next few sessions matter for whether the selloff stabilizes or continues.

2026-07-15eventELEVATE-45-201 Cohort 1 data remain the next clean platform proof pointHigh impact

Entrada said ENTR-601-45 Cohort 1 dosing is underway and the company remains on track to report Cohort 1 data in mid-2026, giving investors a second Duchenne exon-skipping readout after the mixed initial ENTR-601-44 reaction [#8-K-2026-05-07].

2026-12-31eventENTR-601-44 open-label plus Cohort 2 data are now critical to repairing the thesisHigh impact

Following lower-than-expected pediatric plasma exposure in Cohort 1, management said updated PK modeling supports higher exposure at 12 mg/kg and expects ELEVATE-44-201 open-label and Cohort 2 data by year-end 2026; stronger exposure, dystrophin and function data are now the main recovery catalyst [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology